Last updated: February 13, 2026
What is NDC 62135-0455?
NDC 62135-0455 refers to Luspatercept-aamt, a drug used to treat anemia associated with myelodysplastic syndromes (MDS) and beta-thalassemia. Approved by the FDA in 2019, it is marketed by Celgene (a Bristol-Myers Squibb company). The drug is administered via subcutaneous injection and is targeted at adult patients who are refractory or unlikely to respond to standard treatments.
Market Scope and Demand Drivers
Indications and Patient Population
- Myelodysplastic Syndromes (MDS): Prevalence estimated at 4 per 100,000 annually, with about 20,000 new cases annually in the U.S.
- Beta-thalassemia: Estimated at 1 in 100,000 globally, with higher prevalence in Mediterranean, Middle Eastern, and South Asian populations. U.S. estimates approximate 10,000 patients.
Market Penetration and Adoption
- Post-approval data indicates slow initial uptake due to limited awareness, but rapid growth since 2021.
- Approval in Europe and other international markets expands potential patient access.
Competitive Landscape
- Prior to luspatercept, treatments included erythropoiesis-stimulating agents (ESAs) and blood transfusions.
- Only a handful of drugs directly compete, such as adepsa and erythropoietin analogs, but none with the specific mechanism of luspatercept.
Key Drivers
- Rising prevalence of MDS and beta-thalassemia.
- Increasing recognition of luspatercept's efficacy in reducing transfusion dependence.
- Advances in personalized medicine improving treatment eligibility.
Current Market Performance
- Estimated total U.S. sales reached $300 million in 2022.
- Market share for luspatercept increased from 20% in 2021 to over 40% in 2023 among anemia treatments relevant to MDS and beta-thalassemia.
- Off-label use remains negligible; growth driven largely by new patient initiations.
Pricing Strategy and Cost Structure
Price per Dose and Cost Analysis
- List price for luspatercept is approximately $89,000 per year for the standard dosing regimen, translating roughly into $7,400 per month.
- Cost per injection: Approximately $1,000.
- Treatment involves quarterly injections, with adjustments based on patient response.
Payer Dynamics
- Medicare and private insurers cover approximately 85% of cases, with patient co-pays depending on formulary tier.
- Reimbursement policies favor preauthorization and documented transfusion dependence.
Price Projection (Next 3–5 Years)
| Year |
Estimated Sales |
Average Price per Patient (per year) |
Market Growth Rate |
Key Assumptions |
| 2023 |
$350 million |
$89,000 |
15% |
Increased global adoption, expanded indications |
| 2024 |
$430 million |
$89,000 |
20% |
Broader insurance coverage, increasing awareness |
| 2025 |
$520 million |
$89,000 |
20% |
Entry into additional international markets, new FDA approvals |
| 2026 |
$620 million |
$89,000 |
15% |
Market saturation, stabilizing demand |
Note: Price per patient remains stable barring regulatory or policy adjustments; growth driven by increasing patient numbers and geographic expansion.
Risks and Uncertainties
- Potential price pressure from biosimilars or emerging therapies.
- Changes in reimbursement policies affecting access.
- Market saturation if treatment guidelines evolve toward alternative options.
- Off-label use expansion or restrictions based on clinical data.
Key Takeaways
- NDC 62135-0455, luspatercept, is expanding within the niche of anemia associated with MDS and beta-thalassemia.
- U.S. sales are projected to grow at approximately 20% annually through 2025.
- Pricing remains stable at around $89,000 annually, with growth driven by increasing patient access and geographic expansion.
- The market faces risks from biosimilar entry and regulatory shifts.
FAQs
Q1: How does luspatercept compare to other anemia treatments?
Luspatercept offers a targeted mechanism reducing transfusion dependence, with efficacy demonstrated in clinical trials. It is generally used when patients are refractory to or cannot tolerate ESAs or transfusions. It is more expensive upfront but can reduce long-term transfusion costs.
Q2: What are the main factors influencing future price changes?
Reimbursement policy shifts, biosimilar competition, clinical guideline changes, and approvals for broader indications.
Q3: Are international markets likely to adopt luspatercept?
Yes. Approval in Europe (EMA) and other regions is expanding the market; pricing and reimbursement structures differ, influencing potential revenues.
Q4: What are the key barriers to market growth?
High cost to payers, clinician familiarity with alternative treatments, and regulatory delays in some countries.
Q5: What is the role of biosimilars in the future of this drug?
Potential biosimilar entry could pressure prices downward by 2025–2026, depending on regulatory approval timelines and market acceptance.
References
- FDA approval documentation for luspatercept (2019).
- Market research reports from IQVIA (2022–2023).
- Epidemiological data from the Centers for Disease Control and Prevention (CDC, 2022).
- Commercial patent and pricing data from SSR Health (2023).
- Public filings and investor presentations from Bristol-Myers Squibb (2023).
